Eyal C. Attar - Net Worth and Insider Trading

Eyal C. Attar Net Worth

The estimated net worth of Eyal C. Attar is at least $124,933 dollars as of 2024-06-21. Eyal C. Attar is the CHIEF MEDICAL OFFICER of Vor Biopharma Inc and owns about 96,063 shares of Vor Biopharma Inc (VOR) stock worth over $115,276. Eyal C. Attar is also the SVP, Chief Medical Officer of Aprea Therapeutics Inc and owns about 2,367 shares of Aprea Therapeutics Inc (APRE) stock worth over $9,657. Details can be seen in Eyal C. Attar's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Eyal C. Attar has not made any transactions after 2024-06-03 and currently still holds the listed stock(s).

Transaction Summary of Eyal C. Attar

To

Eyal C. Attar Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Eyal C. Attar owns 2 companies in total, including Aprea Therapeutics Inc (APRE) , and Vor Biopharma Inc (VOR) .

Click here to see the complete history of Eyal C. Attar’s form 4 insider trades.

Insider Ownership Summary of Eyal C. Attar

Ticker Comapny Transaction Date Type of Owner
APRE Aprea Therapeutics Inc 2022-02-28 SVP & Chief Medical Officer
VOR Vor Biopharma Inc 2024-06-03 Chief Medical Officer

Eyal C. Attar Latest Holdings Summary

Eyal C. Attar currently owns a total of 2 stocks. Among these stocks, Eyal C. Attar owns 96,063 shares of Vor Biopharma Inc (VOR) as of June 3, 2024, with a value of $115,276 and a weighting of 92.27%. Eyal C. Attar also owns 2,367 shares of Aprea Therapeutics Inc (APRE) as of February 28, 2022, with a value of $9,657 and a weighting of 7.73%.

Latest Holdings of Eyal C. Attar

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
VOR Vor Biopharma Inc 2024-06-03 96,063 1.20 115,276
APRE Aprea Therapeutics Inc 2022-02-28 2,367 4.08 9,657

Holding Weightings of Eyal C. Attar


Eyal C. Attar Form 4 Trading Tracker

According to the SEC Form 4 filings, Eyal C. Attar has made a total of 1 transactions in Vor Biopharma Inc (VOR) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Vor Biopharma Inc is the sale of 14,645 shares on June 3, 2024, which brought Eyal C. Attar around $20,357.

According to the SEC Form 4 filings, Eyal C. Attar has made a total of 3 transactions in Aprea Therapeutics Inc (APRE) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in Aprea Therapeutics Inc is the sale of 1,800 shares on February 28, 2022, which brought Eyal C. Attar around $62,280.

Insider Trading History of Eyal C. Attar

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Eyal C. Attar Trading Performance

GuruFocus tracks the stock performance after each of Eyal C. Attar's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Eyal C. Attar is 115.11%. GuruFocus also compares Eyal C. Attar's trading performance to market benchmark return within the same time period. The performance of stocks bought by Eyal C. Attar within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Eyal C. Attar's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Eyal C. Attar

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 19.41 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 14.43 LIMIT LIMIT LIMIT LIMIT LIMIT

Eyal C. Attar Ownership Network

Ownership Network List of Eyal C. Attar

No Data

Ownership Network Relation of Eyal C. Attar

Insider Network Chart

Eyal C. Attar Owned Company Details

What does Aprea Therapeutics Inc do?

Who are the key executives at Aprea Therapeutics Inc?

Eyal C. Attar is the SVP & Chief Medical Officer of Aprea Therapeutics Inc. Other key executives at Aprea Therapeutics Inc include President & CEO Oren Gilad , SrVP/CFO/Prin. Fin &Acctg. Off John P. Hamill , and director & President & CEO Christian S Schade .

Aprea Therapeutics Inc (APRE) Insider Trades Summary

Over the past 18 months, Eyal C. Attar made no insider transaction in Aprea Therapeutics Inc (APRE). Other recent insider transactions involving Aprea Therapeutics Inc (APRE) include a net purchase of 16,957 shares made by Bernd R. Seizinger , a net purchase of 6,860 shares made by Henneman John B Iii , and a net purchase of 2,000 shares made by Oren Gilad .

In summary, during the past 3 months, insiders sold 0 shares of Aprea Therapeutics Inc (APRE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aprea Therapeutics Inc (APRE) were sold and 26,827 shares were bought by its insiders, resulting in a net purchase of 26,827 shares.

Aprea Therapeutics Inc (APRE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aprea Therapeutics Inc Insider Transactions

No Available Data

Eyal C. Attar Mailing Address

Above is the net worth, insider trading, and ownership report for Eyal C. Attar. You might contact Eyal C. Attar via mailing address: 535 Boylston Street, Boston Ma 02116.

Discussions on Eyal C. Attar

No discussions yet.